Inebilizumab (Uplizna) has been cleared for neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is now the first and only B cell-depleting antibody approved for the disease. Source: AAO
This retrospective study evaluated the features and outcomes of eyes with retinal vasculitis and inflammation after brolucizumab treatment for neovascular AMD. Source: AAO
This case study details 5 patients with nonremitting conjunctivitis that was the sole presenting sign and symptom of COVID-19. Source: AAO
This study evaluated a smartphone-based, gold nanoparticle-based immunoassay paper sensor for identifying a biomarker for diabetic retinopathy (DR). Source: AAO
This large retrospective study evaluated the outcomes of selective laser trabeculoplasty. Source: AAO
This week, the FDA approves a new objective sign for dry eye, researchers find that humans are oblivious to peripheral color changes and 2 major medical journals retract COVID-19 research. Source: AAO
In this study, clinical and radiologic assessments of orbital lesions were compared against histopathologic diagnosis for concordance. Source: AAO
This study describes 2 patients who developed cranial neuropathies within days of presenting with SARS-CoV-2-related respiratory symptoms. Source: AAO
The American Medical Association (AMA) has elected David H. Aizuss, MD, to its board of trustees. Source: AAO
The incidence of retinal vasculitis and retinal vascular occlusion after brolucizumab injections are higher than originally reported, according to a post-hoc review of the phase 3 HAWK and HARRIER trials. Source: AAO